These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23103080)

  • 1. IL1 blockade in crystal-induced arthritis: impact of disease duration and the inflammatory syndrome. Comments on the article by Couderc M. et al. "Efficacy of anakinra in articular chondrocalcinosis".
    Verhoeven F; Prati C; Godfrin-Valnet M; Guillot X; Wendling D
    Joint Bone Spine; 2013 Jan; 80(1):115-6. PubMed ID: 23103080
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to the comment by Verhoeven et al. about the article "Efficacy of anakinra in articular chondrocalcinosis--report of three cases" Joint Bone Spine 2012;79:330-1.
    Couderc M; Soubrier M
    Joint Bone Spine; 2013 Jan; 80(1):116. PubMed ID: 23165180
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of anakinra in articular chondrocalcinosis: report of three cases.
    Couderc M; Mathieu S; Glace B; Soubrier M
    Joint Bone Spine; 2012 May; 79(3):330-1. PubMed ID: 22341584
    [No Abstract]   [Full Text] [Related]  

  • 4. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment.
    Diamantopoulos AP; Brodin C; Hetland H; Haugeberg G
    J Clin Rheumatol; 2012 Sep; 18(6):310-1. PubMed ID: 22832289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure.
    Announ N; Palmer G; Guerne PA; Gabay C
    Joint Bone Spine; 2009 Jul; 76(4):424-6. PubMed ID: 19289295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with a Veterans Affairs Medical Center.
    Desmarais J; Chu CQ
    J Rheumatol; 2019 Jul; 46(7):748-750. PubMed ID: 30442822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature.
    Ottaviani S; Brunier L; Sibilia J; Maurier F; Ardizzone M; Wendling D; Gill G; Palazzo E; Meyer O; Dieudé P
    Joint Bone Spine; 2013 Mar; 80(2):178-82. PubMed ID: 23022422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease.
    Altomare A; Corrado A; Maruotti N; Cici D; Cantatore FP
    Mol Biol Rep; 2021 May; 48(5):4789-4796. PubMed ID: 34075537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis.
    Moltó A; Ea HK; Richette P; Bardin T; Lioté F
    Joint Bone Spine; 2012 Dec; 79(6):621-3. PubMed ID: 22658375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
    Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
    Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report.
    Guignard S; Dien G; Dougados M
    Clin Exp Rheumatol; 2007; 25(5):758-9. PubMed ID: 18078628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature.
    Aouba A; Deshayes S; Frenzel L; Decottignies A; Pressiat C; Bienvenu B; Boue F; Damaj G; Hermine O; Georgin-Lavialle S
    Mediators Inflamm; 2015; 2015():792173. PubMed ID: 25922564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of resistant pseudogout with anakinra.
    McGonagle D; Tan AL; Madden J; Emery P; McDermott MF
    Arthritis Rheum; 2008 Feb; 58(2):631-3. PubMed ID: 18240249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease.
    Naumann L; Feist E; Natusch A; Langen S; Krause A; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2010 Feb; 69(2):466-7. PubMed ID: 20107032
    [No Abstract]   [Full Text] [Related]  

  • 15. [Indications of anakinra].
    Chauffier K; London J; Beaudouin C; Fautrel B
    Presse Med; 2009 May; 38(5):799-807. PubMed ID: 19278814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study.
    Kosmidis ML; Alexopoulos H; Tzioufas AG; Dalakas MC
    J Neurol Sci; 2013 Nov; 334(1-2):123-5. PubMed ID: 23998706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome.
    Kluger N; Rivière S; Guillot B; Bessis D
    Acta Derm Venereol; 2008; 88(3):287-8. PubMed ID: 18480937
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases.
    Botsios C; Sfriso P; Ostuni PA; Todesco S; Punzi L
    Rheumatology (Oxford); 2007 Jun; 46(6):1042-3. PubMed ID: 17449489
    [No Abstract]   [Full Text] [Related]  

  • 19. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report.
    Furlan A; Botsios C; Ruffatti A; Todesco S; Punzi L
    Joint Bone Spine; 2008 May; 75(3):366-7. PubMed ID: 18068393
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.